Methods and dosing regimens using ibudilast and a second agent for cancer therapy

A method of treating a patient diagnosed with glioblastoma or suffering from recurrent glioblastoma comprising:

• administering to the patient a therapeutically effective amount of ibudilast or a pharmaceutically acceptable salt thereof and at least one or more other therapeutic agent;
• wherein the at least one or more other therapeutic agent is temozolomide (TMZ), carmustine, bevacizumab, procarbazine, hydroxyurea, irinotecan, lomustine, nimotuzumab, sirolimus, mipsagargin, cabozantinib, onartuzumab, patupilone (epothilone B), recombinant oncolytic poliovirus (PVS-RIPO), or any combination of one or more of the foregoing;
• wherein ibudilast or a pharmaceutically acceptable salt thereof and the at least one or more other therapeutic agent are administered during an optionally repeating dosing cycle lasting from about 20 to about 40 days;
• wherein the at least one or more other therapeutic agent is administered during only the first about 3 to about 7 days of each dosing cycle;
• wherein the patient expresses unmethylated MGMT;
• and
• wherein ibudilast or a pharmaceutically acceptable salt thereof is administered orally.